Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.

Autor: Lenis AT; Urology Section, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Ravichandran V; Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Brown S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Alam SM; Urology Section, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Katims A; Urology Section, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Truong H; Urology Section, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Reisz PA; Urology Section, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Vasselman S; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Nweji B; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Autio KA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Morris MJ; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Slovin SF; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Rathkopf D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Danila D; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Woo S; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Vargas HA; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Laudone VP; Urology Section, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Ehdaie B; Urology Section, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Reuter V; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Arcila M; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Berger MF; Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Viale A; Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Scher HI; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Schultz N; Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Gopalan A; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Donoghue MTA; Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York., Ostrovnaya I; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York., Stopsack KH; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Solit DB; Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York., Abida W; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3894-3903.

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Autor: Chen N; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., McGrath CB; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Ericsson CI; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Vaselkiv JB; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Rencsok EM; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.; Harvard-MIT Division of Health Sciences and Technology, Harvard Medical School, Boston, Massachusetts., Stopsack KH; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Guard HE; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts., Autio KA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Rathkopf DE; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Enting D; Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom., Bitting RL; Durham VA Health Care System, Durham, North Carolina., Mateo J; Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital Campus, Barcelona, Spain., Githiaka CW; Department of Surgery, University of Nairobi, Nairobi, Kenya., Chi KN; BC Cancer, Vancouver, British Columbia, Canada., Cheng HH; University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington., Davis ID; Monash University Faculty of Medicine, Melbourne, Australia.; Eastern Health, Melbourne, Australia., Anderson SG; The Glasgow-Caribbean Centre for Development Research and the Caribbean Institute of Health Research, The University of the West Indies, Bridgetown, Barbados.; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania., Badal SAM; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania.; The University of the West Indies Mona, Kingston, Jamaica., Bjartell A; Department of Urology, Skåne University Hospital, Malmö, Sweden., Russnes KM; Department of Oncology, Oslo University Hospital, Oslo, Norway., Heath EI; Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, Michigan., Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Henegan JC; Department of Medicine, University of Mississippi Medical Center, Jackson, Mississippi., Hyslop T; Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania., Esteban E; Department of Medical Oncology, Hospital Universitario Central of Asturias, ISPA, Oviedo, Spain., Omlin A; OnkoZentrum, Zurich, Switzerland., McDermott R; St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland., Fay AP; PUCRS School of Medicine, Hospital Nora Teixeira, Porto Alegre, Brazil., Popoola AA; University of Ilorin, Ilorin, Nigeria., Ragin C; African-Caribbean Cancer Consortium, Philadelphia, Pennsylvania.; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Nowak J; Cancer ABCs, Brooklyn, New York., Gerke T; Prostate Cancer Clinical Trials Consortium, New York, New York., Kantoff PW; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., George DJ; Durham VA Health Care System, Durham, North Carolina., Penney KL; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Mucci LA; Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

Publikováno v: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2024 Mar 01; Vol. 33 (3), pp. 419-425.

Evaluating Immune-Related Adverse Events Using PRO-CTCAE in a Phase II Study of Ipilimumab for Hormone-Sensitive Prostate Cancer.

Autor: de Almeida DVP; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Oncology, Oncoclinicas Group, Brasilia, Brazil., Anderson JM; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; School of Medicine, New York Medical College, Valhalla, NY, USA., Danila DC; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA., Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA., Slovin SF; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA., Abida W; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA., Cohn ED; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; School of Medicine, New York University, New York, NY, USA., Baser RE; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Scher HI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA.; Biomarker Development Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Autio KA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, Weill Cornell Medicine, New York, NY, USA.

Publikováno v: Journal of immunotherapy and precision oncology [J Immunother Precis Oncol] 2023 Dec 02; Vol. 6 (4), pp. 162-169. Date of Electronic Publication: 2023 Dec 02 (Print Publication: 2023).

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC).

Autor: Autio KA; Memorial Sloan Kettering Cancer Center, New York, New York, USA autiok@mskcc.org., Higano CS; University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Nordquist L; Urology Cancer Center, Omaha, Nebraska, USA., Appleman LJ; UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, USA., Zhang T; Duke Cancer Institute, Durham, North Carolina, USA.; UT Southwestern Medical Center, Dallas, Texas, USA., Zhu XH; Northwell Health Cancer Institute, New Hyde Park, New York, USA., Babiker H; University of Arizona Cancer Center, Tucson, Arizona, USA., Vogelzang NJ; Comprehens Cancer Centers of Nevada, Las Vegas, Nevada, USA., Prasad SM; Morristown Medical Center/Atlantic Health System, Morristown, New Jersey, USA., Schweizer MT; University of Washington, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA., Madan RA; National Cancer Institute, Bethesda, Maryland, USA., Billotte S; Pfizer Inc, New York, New York, USA., Cavazos N; Pfizer Inc, New York, New York, USA., Bogg O; Pfizer Inc, New York, New York, USA., Li R; Pfizer Inc, New York, New York, USA., Chan K; Pfizer Inc, New York, New York, USA., Cho H; Pfizer Inc, New York, New York, USA., Kaneda M; Pfizer Inc, New York, New York, USA., Wang IM; Pfizer Inc, New York, New York, USA., Zheng J; Pfizer Inc, New York, New York, USA., Tang SY; Pfizer Inc, New York, New York, USA., Hollingsworth R; Pfizer Inc, New York, New York, USA., Kern KA; Pfizer Inc, New York, New York, USA., Petrylak DP; Yale University Cancer Center, New Haven, Connecticut, USA.

Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2023 Mar; Vol. 11 (3).